Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy L Swanson

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Frontiers in Molecular Neuroscience|September 29, 2025
Neuroprotection against beta-amyloid toxicity by the novel estrogen receptor modulator STX requires convergent signaling pathwaysHun-Joo Lee, Zoe Bostick, John Doherty, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 10, 2020
Fentanyl but not Morphine Interacts with Nonopioid Recombinant Human Neurotransmitter Receptors and TransportersRandy Torralva, Amy J Eshleman, Tracy L Swanson, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 20, 2023
Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)<sub>2A</sub> Receptor (5-HT<sub>2A</sub>R), 5-HT<sub>2C</sub>R, 5-HT<sub>1A</sub>R, and Serotonin TransporterLaura B Kozell, Amy J Eshleman, Tracy L Swanson, et al.
Disease Models & Mechanisms|May 21, 2011
A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease: isradipine as a candidate drugPhilip F Copenhaver, Thimmappa S Anekonda, Derek Musashe, et al.
European Journal of Medicinal Chemistry|February 14, 2021
New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263Edward Ofori, Edem K Onyameh, Uma M Gonela, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 7, 2024
Pharmacologic Characterization of Substituted Nitazenes at <i>μ</i>, <i>κ</i>, and <i>Δ</i> Opioid Receptors Suggests High Potential for ToxicityLaura B Kozell, Amy J Eshleman, Katherine M Wolfrum, et al.
ACS Omega|June 26, 2023
Enantiomeric Separation, Absolute Configuration by X-ray Crystallographic Analysis, and Functional Evaluation of Enantiomers of the Dual Ligand, SYA0340 at 5-HT<sub>1A</sub> and 5-HT<sub>7A</sub> ReceptorsBarbara A Bricker, Chandrashekhar Voshavar, Edem K Onyameh, et al.
ACS Pharmacology & Translational Science|January 15, 2026
Evaluation of the Relationship between Vesicular Monoamine Transporter 2 (VMAT2) Inhibition and Neurologic Adverse Events in Approved DrugsRebecca Racz, Laura B Kozell, Amy J Eshleman, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 25, 2022
A highly D<sub>3</sub>R-selective and efficacious partial agonist (S)-ABS01-113 compared to its D<sub>3</sub>R-selective antagonist enantiomer (R)-ABS01-113 as potential treatments for opioid use disorderEwa Galaj, Guo-Hua Bi, Benjamin Klein, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Frontiers in Molecular Neuroscience|September 29, 2025
Neuroprotection against beta-amyloid toxicity by the novel estrogen receptor modulator STX requires convergent signaling pathwaysHun-Joo Lee, Zoe Bostick, John Doherty, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 10, 2020
Fentanyl but not Morphine Interacts with Nonopioid Recombinant Human Neurotransmitter Receptors and TransportersRandy Torralva, Amy J Eshleman, Tracy L Swanson, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 20, 2023
Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)<sub>2A</sub> Receptor (5-HT<sub>2A</sub>R), 5-HT<sub>2C</sub>R, 5-HT<sub>1A</sub>R, and Serotonin TransporterLaura B Kozell, Amy J Eshleman, Tracy L Swanson, et al.
Disease Models & Mechanisms|May 21, 2011
A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease: isradipine as a candidate drugPhilip F Copenhaver, Thimmappa S Anekonda, Derek Musashe, et al.
European Journal of Medicinal Chemistry|February 14, 2021
New dual 5-HT1A and 5-HT7 receptor ligands derived from SYA16263Edward Ofori, Edem K Onyameh, Uma M Gonela, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 7, 2024
Pharmacologic Characterization of Substituted Nitazenes at <i>μ</i>, <i>κ</i>, and <i>Δ</i> Opioid Receptors Suggests High Potential for ToxicityLaura B Kozell, Amy J Eshleman, Katherine M Wolfrum, et al.
ACS Omega|June 26, 2023
Enantiomeric Separation, Absolute Configuration by X-ray Crystallographic Analysis, and Functional Evaluation of Enantiomers of the Dual Ligand, SYA0340 at 5-HT<sub>1A</sub> and 5-HT<sub>7A</sub> ReceptorsBarbara A Bricker, Chandrashekhar Voshavar, Edem K Onyameh, et al.
ACS Pharmacology & Translational Science|January 15, 2026
Evaluation of the Relationship between Vesicular Monoamine Transporter 2 (VMAT2) Inhibition and Neurologic Adverse Events in Approved DrugsRebecca Racz, Laura B Kozell, Amy J Eshleman, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 25, 2022
A highly D<sub>3</sub>R-selective and efficacious partial agonist (S)-ABS01-113 compared to its D<sub>3</sub>R-selective antagonist enantiomer (R)-ABS01-113 as potential treatments for opioid use disorderEwa Galaj, Guo-Hua Bi, Benjamin Klein, et al.
Pageof 2